Hefiya (Adalimumab)
Biosimilar TNF-alpha inhibitor for autoimmune and inflammatory conditions
Quick Facts About Hefiya
Key Takeaways About Hefiya
- Biosimilar to Humira: Hefiya contains adalimumab and has been shown to be highly similar to its reference product Humira in quality, safety, and efficacy
- Treats multiple conditions: Approved for rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, and uveitis
- TB screening required: All patients must be tested for latent tuberculosis before starting treatment, as TNF inhibitors can reactivate dormant infections
- Self-injection at home: After training from a healthcare professional, patients can inject Hefiya themselves using the pre-filled pen
- Infection risk: Hefiya suppresses the immune system and increases the risk of serious infections – report any signs of fever, persistent cough, or unusual symptoms to your doctor immediately
What Is Hefiya and What Is It Used For?
Hefiya is a biosimilar medicine containing adalimumab, a TNF-alpha inhibitor used to treat autoimmune and inflammatory diseases. It works by blocking tumor necrosis factor alpha, a protein that drives inflammation in conditions such as rheumatoid arthritis, Crohn's disease, and plaque psoriasis.
Hefiya belongs to a class of medicines known as biologic disease-modifying antirheumatic drugs (bDMARDs). It is manufactured by Sandoz and has been approved by the European Medicines Agency (EMA) as a biosimilar to Humira (adalimumab), the original reference product. Biosimilars undergo extensive analytical, non-clinical, and clinical studies to demonstrate that they are highly similar to the reference product with no clinically meaningful differences in safety, purity, or potency.
The active substance in Hefiya, adalimumab, is a fully human monoclonal antibody produced by recombinant DNA technology. It binds specifically and with high affinity to TNF-alpha, a key cytokine involved in the pathogenesis of numerous autoimmune and inflammatory diseases. By neutralizing the biological activity of TNF-alpha, Hefiya reduces the cascade of inflammatory responses that cause tissue damage, joint destruction, and organ dysfunction.
TNF-alpha plays a central role in driving inflammatory processes throughout the body. In rheumatoid arthritis, elevated levels of TNF-alpha in synovial fluid contribute to joint inflammation and cartilage destruction. In inflammatory bowel disease, TNF-alpha promotes mucosal inflammation and ulceration. In psoriasis, it drives keratinocyte proliferation and skin inflammation. By blocking this single cytokine, adalimumab can provide therapeutic benefit across all these diverse conditions.
Approved indications for Hefiya
Hefiya is approved for the treatment of the following conditions in adults and, in some cases, children and adolescents:
- Rheumatoid arthritis (RA): Moderate to severe active RA in adults, usually in combination with methotrexate. Can be used as monotherapy if methotrexate is inappropriate.
- Psoriatic arthritis: Active psoriatic arthritis in adults when previous DMARD therapy has been inadequate.
- Ankylosing spondylitis (AS): Severe active ankylosing spondylitis in adults who have had an inadequate response to conventional therapy.
- Axial spondyloarthritis: Severe axial spondyloarthritis without radiographic evidence of AS in adults with inadequate response to NSAIDs.
- Crohn's disease: Moderate to severe active Crohn's disease in adults and children (aged 6 years and older) who have had an inadequate response to conventional therapy.
- Ulcerative colitis: Moderate to severe active ulcerative colitis in adults who have had an inadequate response to conventional therapy.
- Plaque psoriasis: Moderate to severe chronic plaque psoriasis in adults and children (aged 4 years and older) who are candidates for systemic therapy.
- Hidradenitis suppurativa (HS): Active moderate to severe hidradenitis suppurativa in adults and adolescents from 12 years of age with an inadequate response to conventional systemic therapy.
- Non-infectious uveitis: Non-infectious intermediate, posterior and panuveitis in adults who have had an inadequate response to corticosteroids or as a steroid-sparing treatment.
A biosimilar is a biological medicine that is highly similar to an already approved biological medicine (the reference product). Biosimilars are not generic medicines – they are complex proteins produced by living cells. To be approved, a biosimilar must demonstrate comparable quality, safety, and efficacy to the reference product through rigorous scientific comparison. The EMA and FDA have established robust regulatory pathways to ensure biosimilars meet the same high standards as their reference products.
What Should You Know Before Taking Hefiya?
Before starting Hefiya, you must be screened for tuberculosis and other infections. Hefiya should not be used if you have active tuberculosis, severe infections, or moderate to severe heart failure. Tell your doctor about all medications you are taking, your vaccination history, and whether you are pregnant or planning to become pregnant.
Hefiya is a powerful immunosuppressive medicine that requires careful patient selection and monitoring. Your prescribing doctor – typically a specialist in rheumatology, gastroenterology, dermatology, or ophthalmology – will conduct a thorough assessment before initiating treatment. This assessment includes a complete medical history, physical examination, and specific screening tests to minimize the risk of serious adverse events.
Contraindications
Hefiya must not be used in patients with:
- Hypersensitivity to adalimumab or any of the excipients in the formulation
- Active tuberculosis or other severe infections such as sepsis and opportunistic infections
- Moderate to severe heart failure (NYHA class III/IV), as TNF inhibitors may worsen heart failure
Warnings and Precautions
Several important warnings apply to the use of Hefiya. Patients and healthcare providers should be aware of the following risks:
Infections: TNF-alpha is essential for fighting infections. By blocking TNF-alpha, Hefiya impairs the body's ability to mount an adequate immune response. Patients are at increased risk of developing serious infections, including bacterial, viral, fungal, and opportunistic infections. Cases of tuberculosis (including extrapulmonary and disseminated TB), invasive fungal infections (histoplasmosis, coccidioidomycosis, aspergillosis), and infections due to other opportunistic pathogens have been reported. Some of these infections have been fatal.
Tuberculosis: Reactivation of latent tuberculosis is one of the most well-characterized risks of TNF inhibitor therapy. All patients must undergo TB screening before starting Hefiya. This typically involves a tuberculin skin test (TST) or interferon-gamma release assay (IGRA), along with a chest X-ray. If latent TB is detected, prophylactic anti-tuberculosis therapy must be initiated before starting Hefiya. Patients should also be monitored for signs of active TB during and after treatment.
Malignancies: An increased risk of lymphoma and other malignancies, some fatal, has been reported in children and adolescent patients treated with TNF blockers. Hepatosplenic T-cell lymphoma, a rare and often fatal type of lymphoma, has been reported, particularly in adolescent and young adult males with Crohn's disease or ulcerative colitis treated with TNF blockers in combination with azathioprine or 6-mercaptopurine. The role of TNF inhibitor therapy in the development of malignancies is not fully understood.
Hepatitis B reactivation: Reactivation of hepatitis B virus (HBV) has occurred in patients who are chronic carriers and are treated with TNF inhibitors. Some cases have been fatal. Patients should be tested for HBV infection before starting Hefiya.
Contact your doctor immediately if you develop any signs of infection during treatment with Hefiya, including: fever, chills, persistent cough, weight loss, tiredness, night sweats, skin sores, diarrhea, or burning during urination. Early detection and treatment of infections is critical to preventing serious complications.
Pregnancy and Breastfeeding
Adalimumab crosses the placenta and can be detected in the serum of infants born to women treated during pregnancy. The clinical significance of this is uncertain, but infants exposed to adalimumab in utero may be at increased risk of infection. Live vaccines should not be administered to infants exposed to adalimumab in utero for at least 5 months after the mother's last adalimumab injection during pregnancy.
Women of childbearing potential should use adequate contraception during treatment and for at least 5 months after the last dose of Hefiya. If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using Hefiya. Your doctor will weigh the potential benefit of treatment against the potential risk to the unborn child.
Adalimumab is excreted in breast milk at very low concentrations. Because adalimumab is a large protein molecule that is degraded in the gastrointestinal tract, systemic absorption by the breastfed infant is expected to be negligible. However, the decision to continue or discontinue breastfeeding or to continue or discontinue Hefiya therapy should be made in consultation with your healthcare provider.
How Does Hefiya Interact with Other Drugs?
Hefiya can interact with other immunosuppressive medications, live vaccines, and certain biologic therapies. Combining Hefiya with other biologic DMARDs such as anakinra or abatacept is not recommended due to an increased risk of serious infections without additional clinical benefit.
Drug interactions with Hefiya are primarily related to its immunosuppressive mechanism of action. Because Hefiya suppresses TNF-alpha and modulates the immune response, combining it with other immunosuppressive agents can lead to additive immunosuppression and a substantially increased risk of serious infections. Your doctor will carefully review all your current medications before prescribing Hefiya.
Methotrexate is commonly co-prescribed with Hefiya, particularly in rheumatoid arthritis. Clinical studies have shown that the combination of adalimumab and methotrexate is more effective than either agent alone, and methotrexate may also reduce the formation of anti-adalimumab antibodies, which can decrease the drug's efficacy over time. This combination is well-established and generally well-tolerated.
However, the combination of Hefiya with certain other biologic agents is specifically contraindicated or not recommended. Studies of adalimumab in combination with anakinra (an IL-1 receptor antagonist) showed an increased rate of serious infections and neutropenia compared with adalimumab alone, with no additional clinical benefit. Similarly, the combination with abatacept (a T-cell co-stimulation modulator) has been associated with increased rates of infections, including serious infections.
| Interacting Drug | Severity | Effect | Recommendation |
|---|---|---|---|
| Anakinra (Kineret) | Major | Increased risk of serious infections and neutropenia | Do not combine; use one or the other |
| Abatacept (Orencia) | Major | Increased risk of serious infections without added benefit | Do not combine |
| Live vaccines | Major | Risk of vaccine-strain infection due to immunosuppression | Avoid live vaccines during treatment |
| Methotrexate | Moderate | May reduce anti-drug antibody formation; additive immunosuppression | Commonly used together; monitor closely |
| Azathioprine / 6-MP | Moderate | Increased risk of hepatosplenic T-cell lymphoma (rare) | Weigh risks/benefits carefully; monitor |
| Corticosteroids | Minor | Additive immunosuppression; may be used together | May taper corticosteroids after response |
| NSAIDs | Minor | No significant pharmacokinetic interaction | May be used concomitantly |
Vaccinations
Patients on Hefiya should not receive live vaccines. Live vaccines include measles-mumps-rubella (MMR), varicella (chickenpox), oral polio, BCG, yellow fever, and live attenuated influenza vaccine (nasal spray). Inactivated vaccines, including the annual influenza injection and pneumococcal vaccines, can and should be administered to patients on Hefiya, as these patients are at increased risk of infection. It is recommended to bring all vaccinations up to date before starting Hefiya treatment, if possible.
What Is the Correct Dosage of Hefiya?
The standard adult dose of Hefiya for most indications is 40 mg administered by subcutaneous injection every two weeks. Some conditions such as Crohn's disease and ulcerative colitis require a higher initial induction dose. Dosing in children is based on body weight. Your doctor will determine the appropriate dose for your specific condition.
Hefiya treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of the conditions for which Hefiya is indicated. After proper training in injection technique, patients may self-inject Hefiya at home if their physician determines it is appropriate and with medical follow-up as necessary.
Adults
The dosage of Hefiya varies depending on the condition being treated. The following are the standard recommended doses for adult patients:
| Indication | Induction Dose | Maintenance Dose | Notes |
|---|---|---|---|
| Rheumatoid arthritis | 40 mg every 2 weeks | 40 mg every 2 weeks | Often combined with methotrexate. Monotherapy: may increase to 40 mg weekly if response decreases. |
| Psoriatic arthritis | 40 mg every 2 weeks | 40 mg every 2 weeks | May be combined with methotrexate or used as monotherapy. |
| Ankylosing spondylitis | 40 mg every 2 weeks | 40 mg every 2 weeks | Assess response after 12 weeks of treatment. |
| Crohn's disease | 80 mg at week 0, then 40 mg at week 2 | 40 mg every 2 weeks | Accelerated induction: 160 mg week 0, 80 mg week 2 if rapid response needed. |
| Ulcerative colitis | 160 mg week 0, 80 mg week 2 | 40 mg every 2 weeks | May combine with immunomodulators. Reassess if no response by week 8. |
| Plaque psoriasis | 80 mg at week 0 | 40 mg every 2 weeks starting week 1 | Consider discontinuation if no response after 16 weeks. |
| Hidradenitis suppurativa | 160 mg at week 0, 80 mg at week 2 | 40 mg weekly starting week 4 | Reassess if no improvement after 12 weeks of weekly dosing. |
| Non-infectious uveitis | 80 mg at week 0 | 40 mg every 2 weeks starting week 1 | May be initiated with concurrent corticosteroid taper. |
Children
In pediatric patients, Hefiya dosing is typically weight-based. The following doses apply to approved pediatric indications:
Crohn's Disease (children aged 6 years and older)
- Body weight < 40 kg: Induction – 40 mg at week 0, then 20 mg at week 2. Maintenance – 20 mg every 2 weeks.
- Body weight ≥ 40 kg: Induction – 80 mg at week 0, then 40 mg at week 2. Maintenance – 40 mg every 2 weeks.
Plaque Psoriasis (children aged 4 years and older)
- Body weight 15 to < 30 kg: 20 mg every other week
- Body weight ≥ 30 kg: 40 mg every other week
Juvenile Idiopathic Arthritis (children aged 2 years and older)
- Body weight 10 to < 30 kg: 20 mg every other week
- Body weight ≥ 30 kg: 40 mg every other week
Elderly
No dose adjustment is required for elderly patients. However, elderly patients may be more susceptible to infections, and careful monitoring is recommended. The risk-benefit assessment should take into account the increased baseline infection risk in older adults. There is limited data on the use of adalimumab in patients over 75 years of age.
Missed Dose
If you forget to inject Hefiya on the scheduled day, administer the injection as soon as you remember. Then take the next injection on the originally scheduled date, returning to your regular dosing schedule. Do not inject a double dose to make up for a forgotten injection. If you are unsure about when to administer your next dose, contact your doctor or pharmacist for guidance.
Overdose
The maximum tolerated dose of adalimumab has not been established in humans. In clinical trials, no dose-limiting toxicities were observed. There is no specific antidote for adalimumab overdose. In case of overdose, the patient should be monitored for signs or symptoms of adverse reactions and appropriate supportive treatment should be initiated. Contact your local poison center or seek emergency medical attention if you believe an overdose has occurred.
What Are the Side Effects of Hefiya?
The most common side effects of Hefiya include injection site reactions (pain, redness, swelling), upper respiratory infections, headache, and rash. Serious but less common side effects include serious infections, tuberculosis reactivation, blood disorders, demyelinating diseases, and allergic reactions. Most patients tolerate Hefiya well, but regular monitoring by your doctor is essential.
Like all medicines, Hefiya can cause side effects, although not everybody gets them. Most side effects are mild to moderate and manageable. However, some side effects can be serious and require immediate medical attention. The side effect profile of Hefiya is consistent with that of the reference product adalimumab (Humira), as demonstrated in clinical biosimilarity studies.
The most frequently reported adverse reaction is injection site reactions, which occur in approximately 12–20% of patients. These reactions are generally mild, including redness, itching, pain, or swelling at the injection site, and usually resolve within a few days without specific treatment. Applying a cold pack to the injection site before and after injection may help reduce discomfort.
Very Common (affects more than 1 in 10 people)
- Injection site reactions (pain, redness, itching, swelling, bruising)
- Upper respiratory tract infections (colds, sinusitis, pharyngitis)
Common (affects 1 to 10 in 100 people)
- Lower respiratory tract infections (bronchitis, pneumonia)
- Urinary tract infections
- Herpes virus infections (cold sores, shingles)
- Headache
- Musculoskeletal pain (back pain, muscle pain)
- Abdominal pain, nausea, diarrhea
- Rash, itching
- Elevated liver enzymes
- Fatigue
- Anti-adalimumab antibody formation
Uncommon (affects 1 to 10 in 1,000 people)
- Serious infections (sepsis, joint infection, wound infection)
- Opportunistic infections (tuberculosis, histoplasmosis)
- Skin cancer (non-melanoma)
- Blood disorders (leukopenia, anemia, thrombocytopenia)
- Allergic reactions (urticaria, angioedema)
- Mood disorders (depression, anxiety, insomnia)
- Numbness, tingling (paresthesia)
- Visual disturbances
- Tachycardia, hypertension
- Hair loss (alopecia)
- Psoriasis (new-onset or worsening)
Rare (affects fewer than 1 in 1,000 people)
- Lymphoma and other malignancies
- Hepatosplenic T-cell lymphoma (very rare, mostly in young males)
- Demyelinating disorders (multiple sclerosis-like symptoms, optic neuritis)
- Lupus-like syndrome
- Severe allergic reactions (anaphylaxis)
- Liver failure
- Heart failure (new-onset or worsening)
- Pancytopenia, aplastic anemia
- Interstitial lung disease
- Stevens-Johnson syndrome
Contact your doctor or seek emergency care immediately if you experience: severe allergic reaction (difficulty breathing, facial swelling, hives), signs of serious infection (high fever, severe flu-like symptoms, persistent cough, unexplained weight loss), unusual bruising or bleeding, numbness or tingling in hands or feet, vision changes, or yellowing of the skin or eyes (jaundice).
How Should You Store Hefiya?
Hefiya must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the pre-filled pen in its outer carton to protect from light. A single period of storage at room temperature (up to 25°C / 77°F) for a maximum of 14 days is permitted.
Proper storage of Hefiya is essential to maintain the integrity and efficacy of the medication. As a biological medicine containing a protein (adalimumab), Hefiya is sensitive to temperature extremes, light exposure, and physical agitation. Incorrect storage can lead to protein degradation, reduced potency, and potentially harmful changes in the medication.
Store the Hefiya pre-filled pen in its original carton in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze the medication. If accidentally frozen, the pre-filled pen must be discarded – do not use it even if it has thawed. Keep the pen in its outer carton at all times to protect from light, as exposure to light can degrade the adalimumab protein.
If needed, Hefiya may be stored at room temperature (up to 25°C / 77°F) for a single period of up to 14 days. Once removed from the refrigerator for room-temperature storage, the pen must be used within 14 days or discarded, even if it is returned to the refrigerator. Write the date you remove the pen from the refrigerator on the carton so you can track the 14-day window.
Before injection, remove the pre-filled pen from the refrigerator and allow it to reach room temperature for approximately 15 to 30 minutes. Do not warm Hefiya in any other way – do not use a microwave or place it in hot water. Do not shake the pre-filled pen vigorously, as this may damage the protein. Inspect the solution visually before use: it should be clear and colorless to slightly yellow. Do not use the medicine if the liquid is cloudy, discolored, or contains flakes or particles.
Keep Hefiya out of the sight and reach of children. Do not use this medicine after the expiry date stated on the carton and pre-filled pen label. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of used pens and expired medicine to help protect the environment.
What Does Hefiya Contain?
Hefiya contains adalimumab as the active substance (40 mg per 0.8 mL). The other ingredients include adipic acid, citric acid monohydrate, sodium chloride, mannitol, polysorbate 80, sodium hydroxide, and water for injections. Hefiya does not contain any preservatives.
Each Hefiya 40 mg pre-filled pen contains 40 mg of adalimumab in 0.8 mL of solution. Adalimumab is a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. It has a molecular weight of approximately 148 kilodaltons.
The excipients (inactive ingredients) in Hefiya serve important roles in maintaining the stability, pH, and osmolality of the solution:
- Adipic acid: A buffering agent that helps maintain the pH of the solution
- Citric acid monohydrate: A buffering agent working with adipic acid to maintain pH stability
- Sodium chloride: An osmolality adjuster ensuring the solution is compatible with body tissues
- Mannitol (E421): A sugar alcohol used as a tonicity agent and stabilizer
- Polysorbate 80: A surfactant that prevents protein aggregation and stabilizes the adalimumab molecule
- Sodium hydroxide: Used for pH adjustment during manufacturing
- Water for injections: The solvent for the solution
Hefiya is supplied as a clear, colorless to slightly yellow sterile solution for subcutaneous injection in a pre-filled pen containing a pre-filled syringe. Each carton contains one or two pre-filled pens. The pen is designed for single use only. Not all pack sizes may be marketed in your country.
Patients with known allergies to any of the excipients listed above should inform their healthcare provider before starting treatment. While allergic reactions to excipients are uncommon, polysorbate 80 sensitivity has been rarely reported in some individuals.
Frequently Asked Questions About Hefiya
Hefiya (adalimumab) is a TNF inhibitor used to treat several autoimmune conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. It works by blocking tumor necrosis factor alpha (TNF-alpha) to reduce inflammation and tissue damage in these conditions.
Hefiya is a biosimilar to Humira (adalimumab). This means it contains the same active substance and has been demonstrated through rigorous testing to be highly similar in quality, safety, and efficacy. Biosimilars are approved by the EMA and FDA only after meeting strict regulatory standards. Hefiya may differ in its inactive ingredients and delivery device design, but its clinical performance is comparable to Humira.
Hefiya is administered as a subcutaneous injection (under the skin) using a pre-filled pen. The recommended injection sites are the front of the thighs or the abdomen (at least 5 cm from the navel). You should rotate injection sites and avoid injecting into skin that is tender, bruised, red, or hard. After training from a healthcare professional, you can self-inject at home. Let the pen reach room temperature for 15–30 minutes before injecting.
The most common side effects include injection site reactions (redness, itching, swelling, pain), upper respiratory tract infections, headache, musculoskeletal pain, and rash. Most injection site reactions are mild and resolve within a few days. Serious but rare side effects include serious infections, reactivation of tuberculosis, blood disorders, and lymphoma. Regular monitoring by your doctor helps detect and manage side effects early.
Hefiya should only be used during pregnancy if clearly needed and the benefits outweigh the potential risks. Adalimumab crosses the placenta and may affect the infant's immune system. Infants exposed to adalimumab in utero should not receive live vaccines for at least 5 months after the mother's last injection. Women of childbearing potential should use adequate contraception during treatment and for at least 5 months after the last dose. Always discuss pregnancy plans with your doctor.
Yes. All patients must be screened for latent and active tuberculosis (TB) before starting Hefiya. TNF inhibitors can reactivate latent TB, potentially leading to life-threatening disseminated tuberculosis. Screening typically includes a tuberculin skin test (TST) or interferon-gamma release assay (IGRA) and a chest X-ray. If latent TB is detected, prophylactic anti-TB treatment must be started before beginning Hefiya therapy.
References
- European Medicines Agency (EMA). Hefiya – Summary of Product Characteristics (SmPC). EMA/CHMP, updated 2024. Available at: www.ema.europa.eu
- Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26. doi:10.1002/art.39480
- Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18.
- Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4-22.
- Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific biological and small-molecule treatments. J Eur Acad Dermatol Venereol. 2021;35(2):281-317.
- World Health Organization (WHO). Model List of Essential Medicines. 23rd List. Geneva: WHO; 2023.
- Doevendans E, Schellekens H. Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies. Antibodies (Basel). 2019;8(1):21. doi:10.3390/antib8010021
- Blauvelt A, Lacour JP, Fowler JF Jr, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623-631.
- British National Formulary (BNF). Adalimumab. National Institute for Health and Care Excellence (NICE). 2024.
- U.S. Food and Drug Administration (FDA). Biosimilar and Interchangeable Biologics: More Treatment Choices. FDA, 2024.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, a group of licensed physicians and pharmacists with specializations in clinical pharmacology, rheumatology, gastroenterology, and dermatology.
Content developed by clinical pharmacologists with expertise in biologic therapies and immunosuppressive treatment. All medical claims verified against current EMA SmPC, FDA labeling, and peer-reviewed literature.
Reviewed by the iMedic Medical Review Board according to international guidelines from ACR, EULAR, ECCO, and EuroGuiDerm. Evidence level: 1A (systematic reviews and meta-analyses of randomized controlled trials).
Conflict of Interest: The iMedic editorial team has no financial relationships with pharmaceutical companies. All content is independently funded with no commercial sponsorship.
Last reviewed: | Next scheduled review: